Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas

Hwang, Tsong‐Long; Lee, William R.; Hua, Shu Chiou; Fang, Jia You

doi:10.1016/j.jdermsci.2006.12.011

Cited by 72 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Earlier studies have shown the increased antitumor efficacy of PE-containing Lip loaded with cisplatin or ETP. 29,30 This is also confirmed by loss of tumor suppressor PTeN in BaP-induced tumors in mice pten is a tumor suppressor gene, and loss of PTEN protein was noticed according to progression of tumors. [31][32][33] Thus, in the present study, the expression of PTEN was studied to show the status of progression of tumors in the groups of mice treated with free Dox + free ETP) or DPPC-Lip-(Dox + ETP) or CML-Lip-(Dox + ETP).…”

mentioning

confidence: 76%

See 1 more Smart Citation

Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model

Maswadeh

Aljarbou

Alorainy

et al. 2015

IJN

View full text Add to dashboard Cite

Small unilamellar vesicles from camel milk phospholipids (CML) mixture or from 1,2 dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) were prepared, and anticancer drugs doxorubicin (Dox) or etoposide (ETP) were loaded. Liposomal formulations were used against fibrosarcoma in a murine model. Results showed a very high percentage of Dox encapsulation (~98%) in liposomes (Lip) prepared from CML-Lip or DPPC-Lip, whereas the percentage of encapsulations of ETP was on the lower side, 22% of CML-Lip and 18% for DPPC-Lip. Differential scanning calorimetry curves show that Dox enhances the lamellar formation in CML-Lip, whereas ETP enhances the nonlamellar formation. Differential scanning calorimetry curves also showed that the presence of Dox and ETP together into DPPC-Lip produced the interdigitation effect. The in vivo anticancer activity of liposomal formulations of Dox or ETP or a combination of both was assessed against benzopyrene (BAP)-induced fibrosarcoma in a murine model. Tumor-bearing mice treated with a combination of Dox and ETP loaded into CML-Lip showed increased survival and reduced tumor growth compared to other groups, including the combination of Dox and ETP in DPPC-Lip. Fibrosarcoma-bearing mice treated with a combination of free (Dox + ETP) showed much higher tumor growth compared to those groups treated with CML-Lip-(Dox + ETP) or DPPC-Lip-(Dox + ETP). Immunohistochemical study was also performed to show the expression of tumor-suppressor PTEN, and it was found that the tumor tissues from the group of mice treated with a combination of free (Dox + ETP) showed greater loss of cytoplasmic PTEN than tumor tissues obtained from the groups of mice treated with CML-Lip-(Dox + ETP) or DPPC-Lip-(Dox + ETP).

show abstract

mentioning

confidence: 76%

“…28 Cisplatin showed increased antitumor efficacy in PE-containing Lip. 29 ETP encapsulated in immunomodulator tuftsin-bearing Lip showed increased antitumor activity. 30 The present study was aimed to use anticancer drug combination chemotherapy (coadministration of doxorubicin [Dox] and ETP) in Lip prepared from CML.…”

mentioning

confidence: 95%

Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model

Maswadeh

Aljarbou

Alorainy

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…In vitro [110] PMF (Cesium (Cs) and Rubidium (Rb) nanoparticles) [132][133][134]. Liposomes prepared from these phospholipids were used as drug delivery systems for various anticancer drugs, and have shown promising anticancer activity in the murine/mouse model.…”

Section: Development Efforts On Camel Products Based Anticancer Nanopmentioning

confidence: 99%

“…Incorporation of polyethylene glycol (PEG) derivatives in PE liposomes further enhances its cytotoxicity. Toxicity to normal cells has been reported with commonly used cationic liposomes such as DOTAP, but PE liposomes with negative surface charges overcome such drawback (Table 2) [134][135][136][137].…”

Section: Development Efforts On Camel Products Based Anticancer Nanopmentioning

confidence: 99%

Therapeutic Applications of Camel’s Milk and Urine against Cancer: Current Development Efforts and Future Perspectives

Alebie¹,

Yohannes²,

Worku³

2017

J Cancer Sci Ther

View full text Add to dashboard Cite

“…Such delivery vehicles include nanoparticles (11), liposomes (12,13), matrix gels (14), nanocapsules (15) etc. Liposomes offer an advantage of improving the anticancer activity along with reducing the toxicity of cisplatin.…”

Section: Introductionmentioning

confidence: 99%

Caprylate-Conjugated Cisplatin for the Development of Novel Liposomal Formulation

et al. 2014

View full text Add to dashboard Cite

Abstract. Cisplatin, first (platinum) compound to be evolved as an anticancer agent, has found its important place in cancer chemotherapy. However, the dose-dependent toxicities of cisplatin, namely nephrotoxicity, ototoxicity, peripheral neuropathy, and gastrointestinal toxicity hinder its widespread use. Liposomes can reduce the toxicity of cisplatin and provide a better therapeutic action, but the low lipid solubility of cisplatin hinders its high entrapment in such lipid carrier. In the present investigation, positively charged reactive aquated species of cisplatin were complexed with negatively charged caprylate ligands, resulting in enhanced interaction of cisplatin with lipid bilayer of liposomes and increase in its encapsulation in liposomal carrier. Prepared cisplatin liposomes were found to have a vesicular size of 107.9±6.2 nm and zeta potential of −3.99±3.45 mV. The optimized liposomal formulation had an encapsulation efficiency of 96.03±1.24% with unprecedented drug loading (0.21 mg cisplatin/mg of lipids). The in vitro release studies exhibited a pH-dependent release of cisplatin from liposomes with highest release (67.55 ± 3.65%) at pH 5.5 indicating that a maximum release would occur inside cancer cells at endolysosomal pH. The prepared liposomes were found to be stable in the serum and showed a low hemolytic potential. In vitro cytotoxicity of cisplatin liposomes on A549 lung cancer cell line was comparable to that of cisplatin solution. The developed formulation also had a significantly higher median lethal dose (LD 50 ) of 23.79 mg/kg than that of the cisplatin solution (12 mg/kg). A promising liposomal formulation of cisplatin has been proposed that can overcome the disadvantages associated with conventional cisplatin therapy and provide a higher safety profile.

show abstract

Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas

Cited by 72 publications

References 29 publications

Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model

Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model

Therapeutic Applications of Camel’s Milk and Urine against Cancer: Current Development Efforts and Future Perspectives

Caprylate-Conjugated Cisplatin for the Development of Novel Liposomal Formulation

Contact Info

Product

Resources

About